疫苗及突破感染诱导的SARS-CoV-2特异性抗体对奥密克戎亚型BA.2、XBB.1.5和JN.1的长期中和能力
本研究探讨第三、四、五剂疫苗及突破感染诱导的SARS-CoV-2特异性抗体的长期中和能力。刺突蛋白特异性抗体每剂后约3-4个月半衰期下降,但第三剂后12与24个月水平相当;第四、五剂诱导抗体更高且衰减更慢。第五剂XBB.1.5特异性mRNA疫苗显著提高对XBB.1.5和JN.1的中和能力,未观察到抗体反应耗竭。
要点
- 每剂疫苗后刺突蛋白特异性抗体半衰期约3-4个月,第三剂后12与24个月水平相当。
- 第四、五剂诱导的抗体水平更高且衰减慢于第三剂。
- 第五剂XBB.1.5特异性mRNA疫苗显著提高对XBB.1.5和JN.1的中和能力。
核心结论
- 基于最新关注变异株的更新加强疫苗对于维持对新出现变异株的高中和抗体水平是必要的。
- 重复接种COVID-19疫苗后未观察到疫苗诱导的抗体反应耗竭。
研究设计与样本
- 研究分析了第三、四、五剂COVID-19疫苗及SARS-CoV-2突破感染诱导的SARS-CoV-2特异性抗体的长期中和能力。
主要发现
- 刺突蛋白特异性抗体每剂疫苗后相对快速下降,估计半衰期为3-4个月。
- 第三剂疫苗后,刺突蛋白特异性血清抗体水平在接种后12个月和24个月相当。
- 第四和第五剂疫苗诱导的抗体水平更高,且衰减慢于第三剂后。
- 多次突破感染后核衣壳蛋白特异性抗体水平显著增加。
- 第五剂XBB.1.5亚型特异性mRNA疫苗显著提高抗体对奥密克戎XBB.1.5和JN.1亚型的中和能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The long-term effectiveness of COVID-19 vaccines remains a critical area of study, especially with the emergence of new SARS-CoV-2 subvariants. In this study, we investigated the long-term neutralization capacity of SARS-CoV-2 -specific antibodies induced by the third, fourth and fifth vaccine doses, and by SARS-CoV-2 breakthrough infections. Spike (S)-specific antibodies decline relatively rapidly after each vaccine dose, with an estimated half-life of 3-4 months. However, after the third vaccine dose, S-specific serum antibody levels remained comparable at 12 and 24 months post-vaccination. Antibody levels induced by the fourth and fifth vaccine doses were higher, and the decay was slower than after the third vaccine dose. Additionally, nucleocapsid (N)-specific antibody levels increased significantly following multiple breakthrough infections. The neutralization capacity of the antibodies against Omicron XBB.1.5 and JN.1 subvariants were significantly increased by the fifth, XBB.1.5 subvariant specific, mRNA vaccine dose. Our findings strongly indicate that updated booster vaccines based on the latest s of concern are necessary to sustain high neutralizing antibody levels against emerging variants. No exhaustion of vaccine-induced antibody response was observed after repeated COVID-19 vaccinations.
引用
- Reinholm A, Khan H, Laakso T, et al. Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1. Vaccine. 2025. PMID: 41161045. doi:10.1016/j.vaccine.2025.127894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。